Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Asciminib is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia
is a potent and orally active histone deacetylase inhibitor with potential anti-inflammatory
29)/t17-/m1/s1
there is no marked reduction in serum TG
23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49
trans-Trimethoxyresveratrol 9596 Asciminib is undergoing clinical developmentTrans Trimethoxyresveratrol is a derivative of Resveratrol (RSV),and it may be a more potent anti inflammatory, antiangiogenic and vascular disrupting agent when compared with resveratrol. In vitro: The in vitro study of resveratrol and trans Trimethoxyresveratrol showed rather weak cytotoxic effects on three cancer cell lines (HepG2, MCF 7, and MDA MB 231), which contradicted a previous study reporting that resveratrol inhibited MCF 7 cells with an